Amantadine: Indications, Dosing, and Precautions in Adults
Amantadine is FDA-approved for three primary indications in adults: prophylaxis and treatment of influenza A virus infections, Parkinson's disease, and drug-induced extrapyramidal reactions, with standard dosing of 100 mg twice daily (200 mg/day) for most adults, reduced to 100 mg daily in patients ≥65 years or with renal impairment. 1
Primary Indications
1. Influenza A Virus
- Prophylaxis: Start before or after exposure to influenza A; continue for at least 10 days following known exposure 1
- With vaccination: Continue 2-4 weeks after vaccine administration until protective antibodies develop 1
- Without vaccination: Continue for duration of influenza A activity in community 1
- Treatment: Initiate within 24-48 hours of symptom onset; continue 24-48 hours after symptom resolution 1
Note: While amantadine was historically used for influenza A, resistance has become widespread. The 2004 ACIP guidelines 2 provide dosing recommendations, but newer neuraminidase inhibitors are now preferred when available. Amantadine remains cost-effective when rapid diagnostic testing confirms influenza A 3.
2. Parkinson's Disease
- Standard dose: 100 mg twice daily when used alone 1
- Initial dose for high-risk patients: 100 mg once daily for those with serious medical illnesses or receiving high-dose antiparkinson drugs; increase to twice daily after 1-several weeks if needed 1
- Maximum dose: Up to 400 mg daily in divided doses for suboptimal responders, but requires close physician supervision 1
- Onset: Usually within 48 hours 1
Common pitfall: Patients often experience loss of effectiveness after several months. Address this by either increasing to 300 mg daily or temporarily discontinuing for several weeks before reinitiation 1.
3. Drug-Induced Extrapyramidal Reactions
- Standard dose: 100 mg twice daily 1
- Maximum: Up to 300 mg daily in divided doses for suboptimal response 1
4. Emerging Off-Label Use: Neurological Recovery After Acute Brain Injury
While not FDA-approved, amantadine is increasingly used off-label during acute hospitalization for stroke and traumatic brain injury (TBI). For TBI, evidence suggests benefit when initiated within the first 6 weeks at 100 mg twice daily 4. For stroke, 50-65% of patients show improved arousal, though long-term functional benefits remain unclear 5. This use should be reserved for experienced clinicians managing patients with impaired consciousness.
Dosing Regimens
Standard Adult Dosing (Age <65, Normal Renal Function)
- Influenza A: 200 mg daily as single dose OR 100 mg twice daily 1
- Split dosing reduces CNS side effects if they develop 1
- Parkinson's/Extrapyramidal reactions: 100 mg twice daily 1
Elderly Patients (≥65 Years)
Critical adjustment: Maximum 100 mg daily for both prophylaxis and treatment due to age-related decline in renal function 2, 1
The 2004 ACIP guidelines 2 emphasize that elderly patients, particularly those in nursing homes, require dose reduction to 100 mg/day. This is because chronically ill older persons experience 2-4 times higher serum concentrations and increased CNS/GI side effects at 200 mg/day doses.
Renal Impairment Dosing
Amantadine requires significant dose adjustment based on creatinine clearance 1:
| Creatinine Clearance | Dosing Regimen |
|---|---|
| 30-50 mL/min/1.73m² | 200 mg on day 1, then 100 mg daily |
| 15-29 mL/min/1.73m² | 200 mg on day 1, then 100 mg every other day |
| <15 mL/min/1.73m² | 200 mg every 7 days |
| Hemodialysis | 200 mg every 7 days |
Important: Hemodialysis contributes minimally to amantadine clearance 2, 1. Monitor closely for adverse effects as package insert guidelines provide only approximations; further dose reduction or discontinuation may be necessary 2.
For extended-release formulations, dosing intervals can be extended to 24,48,72,96,120, or 168 hours depending on renal function to maintain similar systemic exposure 6.
Critical Precautions
Dose Reduction Required In:
- Congestive heart failure
- Peripheral edema
- Orthostatic hypotension
- Impaired renal function 1
Adverse Effects Profile
CNS effects (more common with amantadine than rimantadine):
Gastrointestinal effects: Significant with both amantadine and rimantadine 7
Cardiovascular: QTc prolongation (up to 8% in stroke patients) 5
Neurological: Seizures (5-13% in acute stroke/TBI populations) 5
Management strategy: If CNS effects develop with once-daily dosing, split into twice-daily administration 1. The 100 mg daily dose shows CNS side effects at or near placebo levels 1.
Drug Resistance Consideration
For influenza A, viral resistance develops readily through M2 protein ion channel mutations. However, resistant viruses are less virulent and have shorter practical lifespan 3. Use rapid diagnostic testing to confirm influenza A before initiating treatment.
Concomitant Therapy
- With anticholinergics: May produce additional benefit when each provides marginal benefit alone 1
- With levodopa: Can be initiated concurrently for rapid therapeutic benefit; hold amantadine constant at 100-200 mg daily while titrating levodopa 1
- Adding to established levodopa: May smooth fluctuations in improvement 1
Pharmacokinetic Considerations
- Well absorbed orally with wide distribution 9
- Peak concentration: ~7.5 hours post-dose with extended-release; ~11 hours with single dose 10, 6
- Elimination: Primarily renal (glomerular filtration + tubular secretion) 9
- Volume of distribution inversely related to dose, causing logarithmic increase in plasma concentration with increasing doses 9
- Food does not affect bioavailability of extended-release formulations 10